GlassScriptPhysician profile
James M Goldring
NPI 1992715775
$6,663.60
in general payments reported to CMS, 2019-2025
30 companies · $322 in 2025
The $322 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $515 · 2020: $682 · 2021: $968 · 2022: $1,074 · 2023: $1,400 · 2024: $1,702 · 2025: $322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,325 · Education: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,324.78 |
| Education | $100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,038.17 | 2021-2025 | |
| Biogen, INC. | $538.37 | 2019-2025 | Vumerity, Tysabri, Plegridy |
| Emd Serono, INC. | $484.86 | 2019-2025 | Mavenclad |
| Alexion Pharmaceuticals, INC. | $423.91 | 2020-2024 | Ultomiris, Soliris |
| Teva Pharmaceuticals USA, INC. | $418.32 | 2019-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Amgen INC. | $409.31 | 2019-2025 | Uplizna |
| Acadia Pharmaceuticals INC | $375.45 | 2023-2024 | Nuplazid |
| Genentech USA, INC. | $353.75 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Novartis Pharmaceuticals Corporation | $324.52 | 2019-2023 | |
| Pfizer INC. | $313.10 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $294.68 | 2021-2023 | Ponvory |
| Lilly USA, LLC | $286.25 | 2020-2025 | Emgality, Reyvow, Kisunla |
| Genzyme Corporation | $271.28 | 2019-2022 | |
| Allergan, INC. | $209.29 | 2020 | |
| Lundbeck LLC | $183.43 | 2021-2025 | Vyepti |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $124.05 | 2021-2023 | Uplizna |
| Acorda Therapeutics, INC | $74.25 | 2022-2023 | Inbrija, Ampyra |
| Celgene Corporation | $69.14 | 2022 | |
| Supernus Pharmaceuticals, INC. | $66.79 | 2023-2024 | Qelbree |
| Mdd US Operations, LLC | $63.29 | 2024 | Apokyn |
| Avanir Pharmaceuticals, INC. | $60.58 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $49.01 | 2023 | Nuedexta |
| Tg Therapeutics, INC. | $46.77 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $43.35 | 2024 | Aptiom |
| Kyowa Kirin, INC. | $28.44 | 2023 | Nourianz |
| Natus Medical Incorporated | $27.12 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $23.53 | 2022 | |
| Medtronic, INC. | $22.07 | 2024 | Linq II |
| Mylan Specialty L.P. | $20.75 | 2023 | Glatiramer Acetate |
| Biohaven Pharmaceutical Holding Company LTD. | $19.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Goldring listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.